Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides a Corporate Update
Portfolio Pulse from
Nurix Therapeutics reported a strong objective response rate of 75.5% from its Phase 1 study of NX-5948 in patients with relapsed/refractory CLL/SLL. This was announced at the 66th American Society of Hematology Annual Meeting.
January 28, 2025 | 9:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Nurix Therapeutics announced a 75.5% objective response rate in its Phase 1 study of NX-5948 for CLL/SLL, presented at the ASH Annual Meeting. This positive result could boost investor confidence and impact the stock price favorably.
The high response rate in the Phase 1 study is a significant positive development for Nurix Therapeutics, indicating potential efficacy of NX-5948. This could lead to increased investor interest and a positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100